The Deutetrabenazine market focuses on a prescription medication used primarily to treat movement disorders such as tardive dyskinesia and chorea associated with Huntington’s disease. Deutetrabenazine works by regulating dopamine levels in the brain to reduce involuntary muscle movements. Its unique formulation, which includes deuterium, helps provide a more stable drug effect and improved tolerability. As awareness of movement disorders increases and more patients are diagnosed, demand for effective therapies like Deutetrabenazine continues to grow. The market is supported by rising healthcare spending, improved access to neurology care, and ongoing drug research in the neurodegenerative disease segment.
According to Fortune Business Insights, the global deutetrabenazine market was valued at USD 1.69 billion in 2024 and is projected to grow from USD 2.03 billion in 2025 to USD 5.42 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 15.1% during the forecast period. In 2024, North America dominated the market with a significant share of 94.08%.
February 2024: Teva Pharmaceutical Investments Singapore Pte Ltd (TPIS) entered a strategic partnership with Jiangsu Nhwa Pharmaceutical Co., Ltd for the marketing and distribution of Teva’s AUSTEDO (deutetrabenazine) in China.
The rising prevalence of neurodegenerative disorders—particularly Huntington’s disease (HD) and tardive dyskinesia (TD)—is a key growth catalyst. Improved diagnostic awareness, expanded access to genetic testing, and longer life expectancy in HD patients are contributing to a growing patient population in need of effective therapeutics like deutetrabenazine.
Complex manufacturing, especially the deuteration process, drives up production costs, affecting affordability in emerging economies. Additionally, long-term adverse reactions may hinder adoption, while stringent FDA and EMA requirements—covering post-marketing surveillance and safety monitoring—can delay or complicate product rollout.
A notable opportunity lies in the introduction of extended‑release (XR) formulations to improve patient compliance. In May 2024, Teva launched AUSTEDO XR, simplifying dosing to once-daily administration.
Competitive pressure from other VMAT2 inhibitors such as Xenazine (tetrabenazine) and Ingrezza (valbenazine), along with certain atypical antipsychotics, can limit market penetration due to varying efficacy, side-effect profiles, and pricing.
Teva enjoys a period of exclusivity as the only approved producer of deutetrabenazine via its AUSTEDO brand. To prolong this market advantage, the company is focusing on geographical expansion—particularly in Asia Pacific (China, India, South Korea)—and filing new patents with estimated generic-launch dates pushed beyond 2030.